Androgenetic Alopecia (Female Pattern Hair Loss)
Conditions
Interventions
TP-1222 or 1% minoxidil lotion, administered at a dose of 1 mL
per application, twice daily, to the affected areas of the scalp for
24 weeks.
Sponsors
Seiji Mita
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Age at the time of obtaining informed consent: 20 years or older. (2) Subjects diagnosed with androgenetic alopecia classified as Ludwig Class I or II. (3) Subjects with disease onset within a specified period (4) Subjects meeting predefined hair criteria required for efficacy evaluation
Exclusion criteria
Exclusion criteria: (1) Subjects with serious comorbidities, or with a history of serious hepatic, renal, cardiac, or hematologic disease. (2) Subjects receiving treatment for hypotension or hypertension. (3) Subjects with concomitant skin diseases at the application site other than androgenetic alopecia. (4) Subjects who have participated in another clinical trial and received an investigational product within 16 weeks prior to the start of investigational product administration in this study. (5) Subjects with alopecia other than androgenetic alopecia. (6) Subjects who have received treatments that may affect hair growth (e.g., minoxidil, hormonal treatments, hair regeneration therapies) (7) Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the number of non-vellus hairs | — |
Contacts
Public ContactSelf-Medication Clinical Development Department
Taisho Pharmaceutical Co., LTD.
Outcome results
None listed